Show simple item record

dc.contributor.authorvan de Laar, Marita Jw
dc.contributor.authorBosman, Arnold
dc.contributor.authorPharris, Anastasia
dc.contributor.authorAndersson, Emmi
dc.contributor.authorAssoumou, Lambert
dc.contributor.authorAy, Eva
dc.contributor.authorBannert, Norbert
dc.contributor.authorBartmeyer, Barbara
dc.contributor.authorBrady, Melissa
dc.contributor.authorChaix, Marie-Laure
dc.contributor.authorDescamps, Diane
dc.contributor.authorDauwe, Kenny
dc.contributor.authorFonager, Jannik
dc.contributor.authorHauser, Andrea
dc.contributor.authorLunar, Maja
dc.contributor.authorMezei, Maria
dc.contributor.authorNeary, Martha
dc.contributor.authorPoljak, Mario
dc.contributor.authorvan Sighem, Ard
dc.contributor.authorVerhofstede, Chris
dc.contributor.authorAmato-Gauci, Andrew J
dc.contributor.authorBroberg, Eeva K
dc.date.accessioned2019-09-30T10:24:06Z
dc.date.available2019-09-30T10:24:06Z
dc.date.issued2019-05-01
dc.identifier.issn1560-7917
dc.identifier.pmid31088600
dc.identifier.doi10.2807/1560-7917.ES.2019.24.19.1800390
dc.identifier.urihttp://hdl.handle.net/10147/626841
dc.descriptionA steady increase in HIV drug resistance (HIVDR) has been demonstrated globally in individuals initiating first-line antiretroviral therapy (ART). To support effective use of ART and prevent spread of HIVDR, monitoring is essential. Aim: We piloted a surveillance system for transmitted HIVDR to assess the feasibility of implementation at the European level. Method: All 31 countries in the European Union and European Economic Area were invited to retrospectively submit data on individuals newly diagnosed with HIV in 2015 who were tested for antiviral susceptibility before ART, either as case-based or as aggregate data. We used the Stanford HIV database algorithm to translate genetic sequences into levels of drug resistance. Results: Nine countries participated, with six reporting case-based data on 1,680 individuals and four reporting aggregated data on 1,402 cases. Sequence data were available for 1,417 cases: 14.5% of individuals (n = 244) showed resistance to at least one antiretroviral drug. In case-based surveillance, the highest levels of transmitted HIVDR were observed for nonnucleoside reverse-transcriptase inhibitors (NNRTIs) with resistance detected in 8.6% (n = 145), followed by resistance to nucleoside reverse-transcriptase inhibitors (NRTI) (5.1%; n = 85) and protease inhibitors (2.0%; n = 34). Conclusion: We conclude that standard reporting of HIVDR data was feasible in the participating countries. Legal barriers for data sharing, consensus on definitions and standardisation of interpretation algorithms should be clarified in the process of enhancing European-wide HIV surveillance with drug resistance information.en_US
dc.language.isoenen_US
dc.subjectHIV/AIDSen_US
dc.subjectpilot studyen_US
dc.subjectresistanceen_US
dc.subjectsurveillanceen_US
dc.titlePiloting a surveillance system for HIV drug resistance in the European Union.en_US
dc.typeArticleen_US
dc.source.journaltitleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
refterms.dateFOA2019-09-30T10:24:07Z


Files in this item

Thumbnail
Name:
eurosurv-24-19-3.pdf
Size:
127.6Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record